At the Pharma Market Research Conference (PMRC) US 2019, we demonstrated the value of Multi Criteria Decision Analysis (MCDA) in making business decisions in highly specialised areas, such as MedTech, orphan diseases or other niche areas where only small sample sizes are available.

The MCDA is a decision-support tool that facilitates decision-making involving multiple dimensions or criteria. It is a systematic approach with flexibility of incorporating both qualitative and quantitative data, handling very small sample sizes, and integrating self-explicated conjoint in evaluating the various decision scenarios and options.

Our comparative assessment shows the evaluation of a traditional market landscaping and TPP testing study vs. the market landscaping and TPP testing study using the MCDA versus a traditional conjoint study.

Attendees of this session learned the pros and cons of the MCDA approach, and the added value and applicability this approach may bring for decision makers in the area of MedTech, orphan diseases and or other niche areas.

Date and time: Thursday, 7th of Feb at 9:50 – 10:25
Presenters:

Bill Salokar
Bill Salokar, VP Client Solutions
Ariel Herrlich
Ariel Herrlich, Manager